Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

3.97USD
15 Dec 2017
Change (% chg)

$0.08 (+2.06%)
Prev Close
$3.89
Open
$3.90
Day's High
$3.99
Day's Low
$3.79
Volume
703,902
Avg. Vol
51,929
52-wk High
$10.86
52-wk Low
$2.93

Select another date:

Wed, Dec 6 2017

BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals

* PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC AS OF NOV 6 - SEC FILING Source text: [http://bit.ly/2nzZrC0] Further company coverage:

BRIEF-Oncomed says CEO Paul Hastings to Resume Chairman of Board Responsibilities

* ONCOMED - ‍CHAIRMAN, PRESIDENT, CEO PAUL HASTINGS WILL RESUME CHAIRMAN OF BOARD RESPONSIBILITIES, EFFECTIVE DEC. 4, 2017​

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights

BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence

* OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence

BRIEF-OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial

* OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial Source text for Eikon: Further company coverage:

BRIEF-Oncomed Pharmaceuticals Q2 loss per share $0.40

* Q2 revenue $6.2 million versus $6.7 million Source text for Eikon: Further company coverage:

Select another date: